treatment 📝

Weekly Taxol (Paclitaxel): What It Involves

After EC, the next phase is weekly Taxol (paclitaxel), alongside HER2-targeted therapy (Phesgo). This page explains what a typical weekly Taxol appointment involves and what it’s trying to do before surgery.

Weekly Taxol (Paclitaxel): What It Involves

This is the “how it works” page for the second stage of chemotherapy: weekly Taxol.

Taxol is a different kind of chemotherapy to EC. Instead of damaging DNA directly, it interferes with how cells divide — which makes it particularly effective against fast-growing cancer cells.


What is Taxol?

Taxol is the brand name for paclitaxel, a taxane chemotherapy drug.

In simple terms: it disrupts the “scaffolding” cells need to split into two, which can slow or stop cancer growth.


Why weekly?

Weekly dosing is common because it can:

  • keep a steady treatment intensity
  • sometimes be better tolerated than higher-dose schedules
  • allow clinicians to adjust quickly if side effects build up

What a weekly Taxol appointment typically involves

A typical week can look like this:

  • Blood test(s) to make sure it’s safe to treat
  • Quick review of symptoms (especially numbness/tingling in hands/feet)
  • Pre-meds (often steroids + antihistamines) to reduce infusion reactions
  • Taxol infusion with monitoring
  • Home plan: manage aches, bowel changes, sleep disruption, skin/nail care, and when to call the team

What side effects people often talk about (in plain English)

Everyone’s experience is unique, but common themes with weekly Taxol include:

  • Fatigue (it can accumulate over weeks)
  • Aches and pains (muscle/joint “flu-ish” feelings)
  • Skin and nail changes
  • Neuropathy risk (tingling, numbness, or burning in fingers/toes)

The big one that clinicians track closely is neuropathy, because it can affect day-to-day function and sometimes needs dose changes.


How this fits with HER2-positive treatment

For HER2-positive breast cancer, chemo is often paired with HER2-targeted therapy (for me: Phesgo).

Chemo attacks fast-dividing cells in general; HER2 treatment targets a specific “growth signal” that HER2-positive cancer cells rely on. Together, they aim to maximise the chance of a complete response before surgery.